Skip to content

Cancers & treatments

News & evidence

Living with cancer

Learn & contribute

Loading

A public, cited, editable map of oncology: technologies, targets, products, companies, institutions, pathways, trials, pairings, roadmaps, and ideas. One page per object, with a plain-language TL;DR on every page.

Work in progress. Every fact on this site is being built and checked in the open and may be incomplete, out of date, or wrong. You must do your own research and verify anything here at its primary source before relying on it. Nothing on this site is medical advice; decisions belong with you and your clinicians.

OnCo is an information resource, not medical advice. Nothing here replaces a conversation with a qualified clinician. Never delay care because of something you read here; in an emergency, call your local emergency services. Terms of use

Browse by cancer
Tags
Search
Connections
For me
Navigator
Biomarker matrix
Calculators
Interactions
Decision aids
Checkpoint side effects
Tumour board
Compare
Counts by category
Rankings
Timeline
Year by year
Query builder
Graph explorer
Saved
Body map

Cancers & treatments

News & evidence

Institutions & people

Institutions
Universities
Trial leadership
People
Heroes and heroines
Companies
Startups
Requests for startups
Investors
Company scorecards
Trial sponsors
Manufacturing map
Countries
United States deep dive
India deep dive
China deep dive
Germany deep dive
Israel deep dive
United Kingdom deep dive
Cases by country
Funding flows

Living with cancer

For me
The first 60 days
Appointment prep pack
Side effects
Symptom to test
Report reader
Survivorship planner
Second opinion
Financial help
Free in oncology
Paying for care in the US
NHS coverage
Paying for care in India
Coverage rankings
Cutting cancer care costs
Diet, exercise and lifestyle
Supportive care
Recovery and rejuvenation
Complementary and supportive approaches
Hair loss and regrowth
What comes back after treatment
Heroes and heroines

Learn & contribute

Reading paths
About & methodology
Roadmap
Gaps to fill
Coverage of the field
Review queue
Reviewer roster
Contributors
Idea votes
Teaching packs
Weekly issue
Suggest an edit
Answer quality
Data dictionary
Build on OnCo
Open API
Open data
Open tools
Open source in oncology
The software of oncology
GitHub

© 2026 OnCo. Code MIT. The data are free for individual and educational use with the attribution “Data from OnCo (onco.cc)”, under CC BY-NC 4.0. Commercial use must contact us to pay for the data. Commercial licences. Made with heart and soul by Jude Gomila .

About and methodology Corrections Open API Tags Terms of use Privacy policy GitHub

Loading

Home
Trials
Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer

trialsTrialRecruiting

Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer

A phase 2/3 trial of KRT-232 in endometrial cancer, run by Kartos Therapeutics, Inc., now recruiting.

Overview Connected4

Overview

Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer is a phase 2/3 interventional study registered as NCT05797831 by Kartos Therapeutics, Inc., with 268 participants planned, started 2023-07-17 and due to reach its primary completion in 2025-08. Interventions recorded: Navtemadlin, Navtemadlin Placebo. Conditions listed: Endometrial Cancer. No results are recorded here; the registry entry is the source.

Setting

A Phase 2/3 Study of Navtemadlin as Maintenance Therapy in Subjects With TP53WT Advanced or Recurrent Endometrial Cancer Who Responded to Chemotherapy

Phase

Phase 2/3

Sponsor

Kartos Therapeutics, Inc.

Registry

Started

2023-07-17

Enrolled

268 enrolled

Connected

Similar pages

Trial
KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia Vera
Shares Kartos Therapeutics, KRT-232.
Trial
Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
Shares Kartos Therapeutics, KRT-232.
Trial
A Study to Evaluate the Use of Durvalumab in Combination With Platinum-based Chemotherapy Followed by Durvalumab With Olaparib as First-line Treatment
Shares Advanced or recurrent endometrial cancer, Endometrial cancer.
Person
Vicky Makker
Shares Advanced or recurrent endometrial cancer, Endometrial cancer.
Person
Shannon N. Westin
Shares Advanced or recurrent endometrial cancer, Endometrial cancer.
Trial
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.
Shares Advanced or recurrent endometrial cancer, Endometrial cancer.
Trial
HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer
Shares Advanced or recurrent endometrial cancer, Endometrial cancer.
Trial
SYD985 in Patients With HER2-expressing Recurrent, Advanced or Metastatic Endometrial Carcinoma
Shares Advanced or recurrent endometrial cancer, Endometrial cancer.

cancers

Advanced or recurrent endometrial cancer Endometrial cancer

drugs

Phase 2small molecule

companies

Kartos Therapeutics

Evidence strength34/100 · Emerging

How much and what kind of evidence, not how big the benefit. Click for the breakdown.

Phase 2/3+22
268 enrolled+12
No structured primary endpoint0
Result: recruiting0
No independent replication recorded0

Formula disclosed on the evidence page.

ProvenanceLast edited 2026-09-18 · Jude Gomila · Link 1,018 registry trials to cancer subtype pages by dri… · diff · file

Sources & links

ClinicalTrials.gov NCT05797831

Data

JSON ·

Follow this page

Wrong or missing?

Propose a change with a source. Organisations can update their own records. Every suggestion is reviewed, safety-checked and validated before it goes live; nothing is edited directly.

Suggest an editDiscuss start a thread

Out of date?
Report a readout
How review works

Cancers

Endometrial cancer
Advanced or recurrent endometrial cancer

Products

KRT-232

Companies

Kartos Therapeutics

Not yet reviewedNeeds expert (clinical) review. Review this page or see the review queue and roster.

Model panel commentary is coming to this page: machine commentary, not clinical review.

Machine-readable versions of Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer

JSON record with neighbours
Markdown context for language models
RDF Turtle for this record (its triples, relations and owl:sameAs; the IRI of this record is https://onco.cc/trials/nct05797831/)
All trials as JSON
RDF N-Triples for the whole corpus
Search index: id, kind, name, TL;DR and route for every record
OpenAPI 3.1 description
API root and meta.json
llms.txt

MCP server: npx -y onco-mcp, tools search, get_entity, list_kind, ask, context, compare. This record is get_entity or context with id nct05797831.

WebMCP tools registered on this page: onco_search, onco_get_entity.